Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters
Database
Language
Affiliation country
Publication year range
1.
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.
Sweeney, Daniel A; Tuyishimire, Bonifride; Ahuja, Neera; Beigel, John H; Beresnev, Tatiana; Cantos, Valeria D; Castro, Jose G; Cohen, Stuart H; Cross, Kaitlyn; Dodd, Lori E; Erdmann, Nathan; Fung, Monica; Ghazaryan, Varduhi; George, Sarah L; Grimes, Kevin A; Hynes, Noreen A; Julian, Kathleen G; Kandiah, Sheetal; Kim, Hannah Jang; Levine, Corri B; Lindholm, David A; Lye, David C; Maves, Ryan C; Oh, Myoung-Don; Paules, Catharine; Rapaka, Rekha R; Short, Willam R; Tomashek, Kay M; Wolfe, Cameron R; Kalil, Andre C.
Open Forum Infect Dis ; 10(5): ofad205, 2023 May.
Article in English | MEDLINE | ID: mdl-37206623

ABSTRACT

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL